Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
233
resultados
Última actualización
04/02/2026 [06:59:00]
Resultados 75 a 100 de 233
Resumen de: WO2026024146A1
The present invention relates to a nano-drug delivery system that targets cancer cells in the hypoxic region of tumor microenvironment and a method for preparing same. The novel nano-drug delivery system according to the present invention can capture an extracellular matrix-degrading enzyme and encapsulate an anticancer drug by binding SO3-PEG-amine as a bifunctional ligand to manganese dioxide nanoparticles, thereby significantly improving drug permeability. In addition, through such high drug permeability, cancer cells in the hypoxic region of tumor microenvironment can be effectively killed.
Resumen de: WO2026024242A1
The invention relates to a nanoparticle for use as a drug carrier and the synthesis method of this nanoparticle. In the invention, magnesium/aluminium (Mg/AI) mucoadhesive thiolated layered double hydroxide (nLDHT) nanoparticles are thiolated with L-cysteine and/or thioglycolic acid and/or 2-iminothiolane hydrochloride and/or glutathione and/or N-acetyl cysteine and/or 3-mercaptopropionic acid and/or 6- mercaptohexanoic acid. Thus, nLDHT interacts with the mucin on the surface of the targeted mucosal tissue for a longer period of time and acts with fewer side effects in the target tissues.
Resumen de: CN120787150A
Disclosed is a composition for the treatment of hypercalcitonemia, the composition comprising a lipophilic or hydrophobic component, an amphiphilic emulsifier, a polar liquid carrier, and comprising or without one or more electrolytes wherein the amphiphilic emulsifier forms: a micelle in a polar liquid carrier, the micelle is provided with a lipophilic or hydrophobic core containing a lipophilic or hydrophobic component; and/or self-assembling to form lipidosome with a lipid bilayer structure; and/or other particle configurations.
Resumen de: CN120603809A
Disclosed are: a composition comprising a lipid-like compound; methods of making such compositions; and the use of these compositions in gene delivery applications.
Resumen de: WO2026024218A1
There is provided a polymeric nanoparticle comprising: a hydrophobic synthetic polymer core; and a hydrophilic bioactive shell, wherein the hydrophobic synthetic polymer core and hydrophilic bioactive shell are parts of a bioactive synthetic polymer with a poly(norbornene-dicarboximide) backbone having one or more repeating units selected from the group consisting of general formula (1), (2) and (3). Also provided are a composition comprising bioactive synthetic polymeric nanoparticles, bioactive synthetic polymers, macromolecules for preparing said bioactive synthetic polymers, related methods and uses.
Resumen de: WO2026023606A1
The main purpose of the present invention is to develop a drug delivery system capable of suitably delivering a drug to the heart and/or the diaphragm. The present invention provides: particles for delivering a drug to the heart and/or the diaphragm, the particles having a boronic acid group as a target directional site; and a pharmaceutical composition or the like comprising said particles for delivering a drug.
Resumen de: WO2026022863A1
The present invention discloses extracellular vesicles or EVs designed for targeted delivery of bio- therapeutics and gene editing tools, to the cells and tissues. These engineered EVs comprise novel synthetic signal sequences, which facilitate efficient cargo loading. The EVs further comprise specific targeting moieties to locate and attach to target or recipient cells, components to evade immune system detection and potential rejection, inhibit phagocytosis by immune cells, minimize immunogenicity and reduce the likelihood of immune recognition as foreign entities.
Resumen de: WO2026022651A1
The current invention involves a method of mixing POP with a polysaccharide to obtain an improved injectable tissue matrix. POP is a partially ordered polypeptide and a polysaccharide, in this instance, comprises at least one glycosaminoglycan. The invention involves mixing these compounds in an injectable tissue matrix to increase volume retention, vascularization, and remodeling immune response, all of which are characteristics that would be useful for an injectable dermal filler, and in plastic and reconstructive procedures.
Resumen de: WO2026022658A1
The invention pertains to pharmaceutical formulations, particularly sustained-release nanoparticle injections of nomegestrol acetate. These formulations are designed as lyophilized powder, enhancing the solubility, bioavailability, and therapeutic efficacy of nomegestrol acetate for medical applications. These pharmaceutical formulations are intended for diseases responsive to nomegestrol treatment, such as hormone replacement therapy. The lyophilized powder formulation is easily reconstituted and administered, improving overall patient experience and treatment outcomes
Resumen de: US20260027380A1
The present disclosure relates to treating tumor tissue using magneto-immunotherapy (Mag-IT) techniques. For example, a method may include administering a magnetotherapy treatment to tumor tissue of a subject and administering an immune checkpoint blockade (ICB) treatment to the subject. The magnetotherapy treatment may include positioning a nanoplatform adjacent to or in contact with the tumor tissue and applying a magnetic field to the nanoplatform.
Resumen de: US20260027064A1
A method of making and using nanoparticles that inhibit formation of bacterial biofilm are provided.
Resumen de: US20260027065A1
The present invention relates to: a liver/adipose tissue dual-targeting composite nano-drug carrier comprising drug-containing poly(L-lactide-co-glycolide) (PLGA) nanoparticles and an adipocyte targeting sequence (ATS) peptide that can target prohibitin; a method for preparing same; and uses thereof for medicines and health foods for preventing or treating obesity or obesity-induced metabolic diseases.
Resumen de: US20260027066A1
Disclosed are isolated nanoparticles composed of an extracellular matrix which comprises at least one heparin binding domain and nucleic acid or polyphosphate, as well as compositions comprising the nanoparticles and methods of treating tissue Injury.
Resumen de: US20260027134A1
The invention relates generally to beverage compositions comprising cryogenically produced cannabinoid nanoparticles using cannabinoids made from hemp, and processes for making the same.
Resumen de: AU2024322931A1
Compositions and methods for delivery of nucleic acid therapeutics are disclosed herein. In some embodiments, a composition for treating a subject includes a dynamic hydrogel, and a nucleic acid therapeutic encapsulated by the dynamic hydrogel. The dynamic hydrogel can include a polymer and a plurality of nanoparticles. The polymer can be non-covalently crosslinked with the plurality of nanoparticles.
Resumen de: WO2026021576A1
A nucleic acid lipid nanocarrier, a preparation method therefor, and use thereof. First, provided is a nanocarrier composition for a nucleic acid drug. On the basis that the total molar amount of lipids in the composition is 100%, the composition comprises the following lipid components: greater than or equal to 40% and less than or equal to 50% of ionizable lipid; greater than or equal to 0.5% and less than or equal to 3.0% of PEG-modified lipid; greater than or equal to 30% and less than or equal to 44.5% of steroid; and greater than 15% and less than 22% of helper phospholipid. Also provided are use of the composition in the preparation of a nucleic acid drug nanocarrier and the prepared nucleic acid-loaded drug. The nucleic acid drug nanocarrier can target a treatment site, and the non-liver-targeting lipid nanocarrier has low liver metastasis.
Resumen de: WO2026021204A1
A multifunctional DNA nanosphere, a preparation method therefor, and use thereof. An acid-responsive i-motif sequence, an EGFRvIII aptamer A32 sequence, and an MRI contrast agent Gd-DOTA-N3 are combined to design the DNA nanosphere to achieve MRI enhancement/fluorescence integrated dual development of glioma, so as to obtain a glioma tumor development signal that can meet clinical requirements. Meanwhile, the acid-responsive i-motif sequence, the EGFRvIII aptamer A32 sequence, the MRI contrast agent Gd-DOTA-N3, and a chemotherapeutic drug doxorubicin (DOX) are combined, Gd-DOTA-N3 and Cy5-BHQ fluorescent pairs are modified on specific bases, and using the principle of DNA complementary base pairing, novel multifunctional DNA nanospheres for glioma fluorescence/MRI imaging and treatment are prepared.
Resumen de: WO2026020697A1
The present invention pertains to the technical field of novel biomaterials. Disclosed is use of hyaluronic acid in improving the performance of a polysaccharide-polypeptide composite hydrogel. The present invention, on the basis of the self-assembly characteristics of polypeptides, prepares polysaccharide-polypeptide composite hydrogels with hyaluronic acid (HA) at different concentrations. It has been verified that compared to a single polypeptide hydrogel free of HA, HA reduces the mechanical properties of the composite gels, but can still slow the degradation of the composite hydrogels and improve the stability thereof. HA can also improve the ability of the composite hydrogels to load quercetin and hesperidin, playing a role in slowing the in vitro release of the two, which is conducive to the sustained release of active substances. Moreover, the addition of HA does not affect the secondary structures and micro-nano structures of the composite hydrogels, and can also improve the strength of non-covalent interactions between molecules, improving the stability of the composite hydrogels. The present invention explores the effect of HA on the performance of the composite hydrogels and provides a theoretical basis for the research of hydrophobic drug delivery carriers.
Resumen de: WO2026020280A1
The present disclosure belongs to the technical field of block copolymers, and specifically relates to an amphiphilic block copolymer, a stereocomplex, and a preparation method therefor and the use thereof. The amphiphilic block copolymer contains a polyester block and a water-soluble polymer block. By forming a monomer of the polyester block and introducing a second monomer having stereoregularity on the premise that raw materials, such as D- and L-lactide, are used as a first monomer, the stability of the amphiphilic block copolymer can be improved; in addition, the water solubility or self-dispersibility thereof are still maintained, micelles or nanoparticles are formed, and high drug loading capacity is maintained.
Resumen de: CN120981238A
The present disclosure relates generally to the field of stable compositions comprising particles dispersed in an aqueous phase comprising a buffer system and having a pH of about 4.0 to 5.5, methods for preparing and storing such compositions, and use of such compositions in therapy, and wherein the particle comprises (i) a nucleic acid (e.g., DNA or RNA, in particular mRNA or inhibitory RNA, e.g., siRNA); and (ii) a cationic lipid or a lipid that can ionize cations.
Resumen de: EP4685136A1
The present invention provides an amino lipid, and lipid nanoparticles (LNPs) and a use thereof, the amino lipid having a structure represented by general formula (I), or an isomer, pharmaceutically acceptable salt, prodrug or solvate of the amino lipid. The present invention further provides LNPs containing the amino lipid. According to the present invention, the amino lipid having a structure represented by general formula (I) is used as an ionizable lipid compound, and the LNPs are obtained by means of self-assembly of the ionizable lipid compound, a steroid, a neutral lipid, and a polymer-bonded lipid. The LNPs can further improve the translation expression level of a nucleic acid load in cells, improve the effect of a nucleic acid-LNP preparation, and enable the nucleic acid-LNP preparation to provide a theoretical basis for personalized treatment.
Resumen de: WO2024197065A2
Provided herein are gene editing systems and compositions directed to effectuate in vivo edits in the LPA gene. Treatment or prevention of cardiovascular disease through disruption of the production of apo(a) through genetic editing and the reduction of the blood lipoprotein(a) Lp(a) concentration is disclosed herein. Disclosed are nickase-based gene editing systems designed to effectuate the installation of insertions and/or deletions (indel variants) and/or non-synonymous variants in the coding sequence of LPA. The nickase-based gene editing systems generally comprise one or more mRNAs that encode one or more nickases and a plurality of guide oligonucleotides (e.g., gRNAs) and may be delivered in vivo to a mammalian subject in need thereof via a suitable delivery system, such as lipid nanoparticles (LNPs) (with or without GalNAc targeting moieties) intravenously, or otherwise, administered to a patient as potentially a once-and-done therapeutic. The manufacturing, use, and formulation of the gene editing systems and compositions are also disclosed.
Resumen de: WO2024196422A1
A novel nanostructured nucleic acid platform that uniquely integrates the advantages of a disulfide moiety for the enhanced cytosolic uptake of a DNA or RNA nanostructure ("DNA origami") which can further comprise a therapeutic agent and a targeting moiety is described herein. The targeting moiety can be an affibody, in particular, a Her2 affibody. The disulfide moiety can be formed from a sulfide-modified oligonucleotide designed to target enhanced cystolic uptake.
Resumen de: CN120659770A
Provided herein are lipid compounds, such as compounds of Formula (I), Formula (II), Formula (III), Formula (IV), or Formula (V). Also provided are lipid nanoparticles and pharmaceutical compositions, each comprising a lipid compound, such as a compound of Formula (I), Formula (II), Formula (III), Formula (IV), or Formula (V). # imgabs0 #
Nº publicación: JP2026503201A 28/01/2026
Solicitante:
ウェストジーンバイオファーマシーオーエルティディ
Resumen de: US2025134813A1
The present invention provides a compound, which is a compound represented by formula (I) or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt thereof represented by formula (I):X1, X2, and X3 are each independently a C1-C15 alkyl group optionally substituted; R1 and R2 are each independently a C1-C40 alkyl group optionally substituted, a C1-C40 heteroalkyl group optionally substituted, a C2-C40 alkenyl group optionally substituted, a C2-C40 heteroalkenyl group optionally substituted, a C2-C40 alkynyl group optionally substituted, or a C2-C40 heteroalkynyl group optionally substituted; R3, R4, R5, and R6 are each independently H, halogen, or a C1-C3 alkyl group optionally substituted; the substituent group is independently selected from halogen, —OH, —SH, —NH2, —NO2, cyano, or C1-C3 alkyl. This compound has the advantages of low cytotoxicity, strong delivery capability, and good immunostimulatory effect.
BOPI
Sede Electrónica
